JP2022512901A5 - - Google Patents
Info
- Publication number
- JP2022512901A5 JP2022512901A5 JP2021523933A JP2021523933A JP2022512901A5 JP 2022512901 A5 JP2022512901 A5 JP 2022512901A5 JP 2021523933 A JP2021523933 A JP 2021523933A JP 2021523933 A JP2021523933 A JP 2021523933A JP 2022512901 A5 JP2022512901 A5 JP 2022512901A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- antibody
- sequence
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756065P | 2018-11-05 | 2018-11-05 | |
| US62/756,065 | 2018-11-05 | ||
| US201962848524P | 2019-05-15 | 2019-05-15 | |
| US62/848,524 | 2019-05-15 | ||
| US201962855601P | 2019-05-31 | 2019-05-31 | |
| US62/855,601 | 2019-05-31 | ||
| PCT/US2019/059933 WO2020097127A2 (en) | 2018-11-05 | 2019-11-05 | B-cell activating cd73 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512901A JP2022512901A (ja) | 2022-02-07 |
| JP2022512901A5 true JP2022512901A5 (enExample) | 2022-11-10 |
| JP7650795B2 JP7650795B2 (ja) | 2025-03-25 |
Family
ID=70612455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523933A Active JP7650795B2 (ja) | 2018-11-05 | 2019-11-05 | Ｂ細胞を活性化するｃｄ７３抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220242963A1 (enExample) |
| EP (1) | EP3880710A4 (enExample) |
| JP (1) | JP7650795B2 (enExample) |
| KR (1) | KR20210100099A (enExample) |
| AU (1) | AU2019377454A1 (enExample) |
| CA (1) | CA3118706A1 (enExample) |
| IL (1) | IL282852A (enExample) |
| MX (1) | MX2021005248A (enExample) |
| WO (1) | WO2020097127A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4084870A1 (en) | 2020-01-03 | 2022-11-09 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| CR20220317A (es) | 2020-01-03 | 2022-09-02 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| BR112022020256A2 (pt) * | 2020-04-09 | 2023-01-03 | Aprilbio Co Ltd | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| CN119317449A (zh) * | 2022-03-14 | 2025-01-14 | 上海华奥泰生物药业股份有限公司 | 抗体药物偶联物及其应用 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340569B1 (en) * | 1997-11-12 | 2002-01-22 | University Of Pittsburgh | Monoclonal antibody and antigens specific therefor and methods of using same |
| CA3007646A1 (en) * | 2015-12-09 | 2017-06-15 | Bioatla, Llc | Humanized anti-cd73 antibodies |
| EP3481869A4 (en) * | 2016-07-11 | 2020-02-26 | Corvus Pharmaceuticals, Inc. | ANTI-CD73 ANTIBODIES |
| WO2018187512A1 (en) * | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
-
2019
- 2019-11-05 MX MX2021005248A patent/MX2021005248A/es unknown
- 2019-11-05 EP EP19882254.6A patent/EP3880710A4/en not_active Withdrawn
- 2019-11-05 AU AU2019377454A patent/AU2019377454A1/en not_active Abandoned
- 2019-11-05 US US17/290,961 patent/US20220242963A1/en not_active Abandoned
- 2019-11-05 JP JP2021523933A patent/JP7650795B2/ja active Active
- 2019-11-05 KR KR1020217017020A patent/KR20210100099A/ko not_active Ceased
- 2019-11-05 WO PCT/US2019/059933 patent/WO2020097127A2/en not_active Ceased
- 2019-11-05 CA CA3118706A patent/CA3118706A1/en active Pending
-
2021
- 2021-05-02 IL IL282852A patent/IL282852A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022081468A (ja) | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン | |
| US20230128449A1 (en) | Silicate containing compositions and methods of treatment | |
| JP2007516966A5 (enExample) | ||
| JP2021501214A5 (enExample) | ||
| JP2022515480A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2024531151A5 (enExample) | ||
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| JP2010519180A5 (enExample) | ||
| EA029228B1 (ru) | Способ лечения острых и хронических заболеваний и состояний дыхательных путей и синдрома кашля и комбинированная фармацевтическая композиция, используемая для осуществления способа | |
| JP2009544585A5 (enExample) | ||
| JP2020523384A5 (enExample) | ||
| JP2021534195A5 (enExample) | ||
| RU2011140508A (ru) | Антигены хламидии | |
| JP2022534118A5 (enExample) | ||
| Paderni et al. | Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects | |
| JP2009529915A5 (enExample) | ||
| US20260102504A1 (en) | Glucose-responsive insulin complex, preparation method and use thereof | |
| WO2021182571A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP2009506043A5 (enExample) | ||
| JP2021523096A5 (enExample) | ||
| CN118203565A (zh) | 去甲替林治疗纤维化疾病的药物用途 | |
| CN120676943A (zh) | 使用因子b抑制剂的方法 | |
| WO2015165968A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| EP3518926A1 (en) | USE OF 2-{4-[(4-{[1-CYCLOPROPYL-3-TETRAHYDRO-2H-PYRAN-4-yl)-1H-PYRAZOL-4-yl]OXY}PYRIDINE-2-yl)AMINO]PYRIDIN-2-yl}PROPAN-2-OL IN THE TREATMENT OF CANCER |